

Health Protection scorecard - November 2019

	Significantly worse than England
	Not significantly different to England
	Significantly better than England
	Significance not tested
-	No sub-regional data available
	Above national goal
	Close to national goal
	Below national goal

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Screening	N	2.19 - Cancer diagnosed at early stage (experimental statistics)	%	2017	1,171	49.3%	52.4%	52.2%	—
	N	C24a - Cancer screening coverage - breast cancer	%	2018	49,295	77.8%	77.0%	74.9%	—
	Y	C24b - Cancer screening coverage - cervical cancer (25 - 49 years)	%	2019	62,576	76.7%	74.2%	69.8%	—
	Y	C24c - Cancer screening coverage - cervical cancer (50 - 64 years)	%	2019	38,824	77.3%	76.3%	76.2%	—
	N	C24d - Cancer screening coverage - bowel cancer	%	2018	53,245	61.1%	60.4%	59.0%	—
	N	C25a - Abdominal Aortic Aneurysm Screening - Coverage	%	2017/18	2,616	83.2%	82.3%	80.8%	—
	N	C25b – Diabetic eye screening - uptake (%)	%	2017/18	-	-	84.1%	82.7%	
	N	C25d - Infectious Diseases in Pregnancy Screening – HIV Coverage (%)	%	2017/18	-	-	99.5%	99.6%	
	Y	C25e - Infectious Diseases in Pregnancy Screening – Syphilis Coverage (%)	%	2017/18	-	-	99.5%	99.5%	
	Y	C25f - Infectious Diseases in Pregnancy Screening – Hepatitis B Coverage (%)	%	2017/18	-	-	99.6%	99.5%	
	N	C25g - Sickle Cell and Thalassaemia Screening – Coverage (%)	%	2017/18	-	-	99.5%	99.6%	
	N	C25h - Newborn Blood Spot Screening – Coverage (%)	%	2017/18	-	-	98.6%	96.7%	
	N	C25i - Newborn Hearing Screening – Coverage (%)	%	2017/18	4,912	99.5%	99.0%	98.9%	—
N	C25j - Newborn and Infant Physical Examination Screening – Coverage (%)	%	2017/18	-	-	94.5%	95.4%		

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Imms and Vaccs		12 months							
	Y	D03b - Population vaccination coverage - Hepatitis B (1 year old)	%	2018/19	-	100%	-	-	
	Y	D03c - Population vaccination coverage - Dtap / IPV / Hib (1 year old)	%	2018/19	4,958	97.3%	95.4%	92.1%	
			<90% 90% to 95% ≥95%						
	N	3.03iv - Population vaccination coverage - MenC <i>**From 1st July 2016 the dose of MenC offered at 3 months is to be discontinued and so the 1 year evaluation 3.03iv indicator will become obsolete within the next two years (data for 2016/17 will be the last collection) **</i>	%	2015/16	5,399	98.7%	97.8%	*	
			<90% 90% to 95% ≥95%						
	Y	D03f - Population vaccination coverage - PCV (1 year old)	%	2018/19	4,964	97.4%	95.7%	92.8%	
			<90% 90% to 95% ≥95%						
		24 months							
	Y	D03g - Population vaccination coverage - Hepatitis B (2 years old)	%	2018/19	-	100%	-	-	
	Y	D03h - Population vaccination coverage - Dtap / IPV / Hib (2 years old)	%	2018/19	5,386	98.8%	96.7%	94.2%	
			<90% 90% to 95% ≥95%						
	Y	D03m - Population vaccination coverage - Hib / MenC booster (2 years old)	%	2018/19	5,315	97.5%	94.7%	90.4%	
			<90% 90% to 95% ≥95%						
	Y	D03k - Population vaccination coverage - PCV booster (2 years old)	%	2018/19	5,318	97.5%	94.7%	90.2%	
			<90% 90% to 95% ≥95%						
	Y	D03j - Population vaccination coverage - MMR for one dose (2 years old)	%	2018/19	5,298	97.1%	94.5%	90.3%	
			<90% 90% to 95% ≥95%						
		2-3 years							
	Y	D03l - Population vaccination coverage - Flu (2-3 years old)	%	2018/19	4,874	44.0%	44.4	44.9%	
			<40% 40% to 65% >65%						
		5 years							
	Y	D04b - Population vaccination coverage - MMR for one dose (5 years old)	%	2018/19	5,164	98.1%	96.6%	94.5%	
			<90% 90% to 95% ≥95%						
	N	3.03vi - Population vaccination coverage - Hib / Men C booster (5 years old)	%	2017/18	5,768	97.2%	95.1%	92.4%	
			<90% 90% to 95% ≥95%						
	Y	D04c - Population vaccination coverage - MMR for two doses (5 years old)	%	2018/19	5,077	96.4%	91.4%	86.4%	
			<90% 90% to 95% ≥95%						
	Other Children and young people								
N	D04e - Population vaccination coverage - HPV vaccination coverage for one dose (females 12-13 years old)	%	2017/18	2,487	89.7%	85.5%	86.9%		
		<80% 80% to 90% ≥90%							
N	D04f - Population vaccination coverage - HPV vaccination coverage for two doses (females 13-14 years old)	%	2017/18	2,325	87.9%	85.5%	83.8%		
		<80% 80% to 90% >90%							
	Other								
N	Persons entering substance misuse treatment - Percentage of eligible persons completing a course of hepatitis B vacc		2016/17	32	3.6%	6.0%	8.1%		
Y	D05 - Population vaccination coverage - Flu (at risk individuals)	%	2018/19	33,857	49.0%	49.2%	48.0%		
		<55% ≥55%							
Y	D06a - Population vaccination coverage - Flu (aged 65+)	%	2018/19	78,105	71.4%	73.1%	72.0%		
		<75% %≥75%							
N	D06b - Population vaccination coverage - PPV (aged 65+)	%	2017/18	37,998	70.2%	71.0%	69.5%		
		<65% 65% to 75% ≥75%							
N	D06c - Population vaccination coverage - Shingles vaccination coverage (70 years old)	%	2017/18	3,513	47.6%	45.0%	44.4%	No trend	
		<50% 50% to 60% ≥60%							

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Sexual health	N	D02a - Chlamydia detection rate / 100,000 aged 15-24	R/100,000	2018	980	1504	1815	1975	
			<1,900 1,900 to 2,300 ≥2,300						
	N	D02b - All new STI diagnoses (exc Chlamydia aged <25) / 100,000	R/100,000	2018	1944	586	640	851	
	N	Gonorrhoea diagnosis rate per 100,000 population	R/100,000	2018	288	55	66.5	98.5	
N	Syphilis diagnoses rate per 100,000 population	R/100,000	2018	32	6.1	9.3	13.1		
Y	D07 - HIV late diagnosis (%)	R/100,000	2016-18	20	33.3%	42.9	42.5		
Infectious diseases	N	Legionnaire's disease confirmed incidence rate / 100,000	R/100,000	2016	3	0.57	0.53	0.61	
	Y	Typhoid and paratyphoid confirmed incidence rate / 100,000	R/100,000	2018	2	38.0%	0.15	0.61	
	N	D08b - TB incidence (three year average)	R/100,000	2016-18	31	2	4.4	9.2	
	N	3.05i - Treatment completion for TB (%)*	%	2017	4	50	74.7	84.7	
	N	Measles (reported cases confirmed, Year to date)	R/100,000	Q2 2018	0	0	0.15	-	
	N	Measles new diagnosis rate	R/100,000	2018	1	0.2	0.5	1.7	
	N	<i>Mumps (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2019	14	10.4	1.3	-	
	N	<i>Whooping cough (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2019	6	4.55	3.31	-	
	N	<i>Rubella (confirmed cases, year to date)</i>	R/100,000	Q2 2019	0	0	0	-	No trend
	N	<i>Meningococcal Infection (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2019	1	0.76	1.2	-	
	N	<i>Scarlet Fever (all notifications)</i>	R/100,000	Q2 2019	20	15.2	27.2	-	
	N	<i>Haemophilus Influenzae Type B (HiB)</i>	R/100,000	Q2 2019	0	0	0	-	
	N	Non-typhoidal Salmonella (incidence)	R/100,000	2017	92	17.6	16.6	15.7	
	N	<i>Quarterly Salmonella Enteritidis (incidence)</i>	R/100,000	Q2 2019	5	3.8	3.2	-	
	N	<i>Quarterly Salmonella Typhimurium (incidence)</i>	R/100,000	Q2 2019	5	3.8	1.8	-	
	N	<i>Quarterly Salmonella other (incidence)</i>	R/100,000	Q2 2019	9	6.8	5.7	-	
	N	Campylobacter (incidence)	R/100,000	2017	689	132	123	97	
	N	<i>Quarterly Campylobacter (incidence)</i>	R/100,000	Q2 2019	168	127.5	126.7	-	
	N	Cryptosporidium (incidence)	R/100,000	2017	75	14.4	10.4	7.3	
	N	<i>Quarterly Cryptosporidium (incidence)</i>	R/100,000	Q2 2019	11	8.3	4.7	-	
	N	Giardia (incidence)	R/100,000	2017	35	6.7	11.9	8.5	
	N	<i>Quarterly Giardia (incidence)</i>	R/100,000	Q2 2019	10	7.6	8.6	-	
	N	STEC serogroup O157 (incidence)	R/100,000	2017	10	1.9	1	1	